ClinicalTrials.gg
RecruitingNCT07221825Updated Oct 15, 2026

Low-Count Quantitative SPECT for Men Treated With Radium-223

An interventional study of Low-count quantitative single-photon emission computed tomography imaging in Prostate Cancer and Cancer of the Prostate, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Planned enrollment
9th of 20
38 · median 35
Started
2026
with 4 others
No phase
12 of 23
4 open now
Primary completion
2028-04
later than 5 of 10 live
Registered
19th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 12 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 19th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. [223Ra]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development.

Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

03

Conditions studied

  • Prostate Cancer
  • Cancer of the Prostate

Browse trials for

Keywords

  • Prostate cancer
  • Bone metastasis
  • SPECT
  • Radiopharmaceutical therapies
  • Theranostics
  • Alpha-particle
  • Xofigo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed castration-resistant prostate cancer with symptomatic bone .
  • Minimum detectable skeletal lesion count of 3.
  • Eligible to receive Xofigo.
  • At least 18 years of age.
  • performance status ≤ 3.
  • Ability to understand and willingness to sign an IRB-approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria - Patients:

  • Predominant visceral disease.
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Concurrent alternative radiopharmaceuticals
  • Inability to maintain stationary supine pose for 45-60 minutes

Eligibility Criteria - Physicians:

  • Medical Oncologist or Radiation Oncologist at Siteman Cancer Center.
  • Treating patients with prostate cancer.
  • Willing to complete Physician Questionnaire during participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    LC-QSPECT

    Consenting and eligible men receiving standard of care (Xofigo) will receive a noninvasive LC-QSPECT scan (\~45 minutes) and a low-dose contrast-enhanced CT after Cycles 1 and 3 of Xofigo. SOC CT and bone scans will also be performed at baseline and after Cycles 3 and 6. Specimen collection will be as follows: bone biopsy (Cycle 1 Day 2) (optional), stool (first bowel movement post-each SPECT scan), and blood for PSA and bone turnover biomarkers (with each cycle of treatment). Additionally, pain will be assessed, and quality of life will be monitored prior to treatment and after each treatment cycle.

    Device: Low-count quantitative single-photon emission computed tomography imaging

  • No intervention
    Physicians

    Additionally, medical oncologists and radiation oncologists who are seeing patients who are enrolled in this study will be considered participants in this study (as they will be completing the Physician Questionnaire).

Interventions

  • DeviceLow-count quantitative single-photon emission computed tomography imaging

    LC-QSPECT scans will be performed between 6 and 36 hours after administration of Xofigo during Cycles 1 and 3.

    Also known as: LC-QSPECT

06

What researchers measure

Primary outcomes

  1. Spearman's correlation coefficient between the LC-QSPECT estimated uptake in the lesions and intestine with ex vivo activity sampling

    The investigators will assess if the correlation (in absolute magnitude) ≥ 0.60 between the tissue and SPECT data against a low correlation of \< 0.2 based on 1-sided normal test at a 5% level.

    Time frame: Through collection of ex vivo sample (estimated to be 3 months)

Secondary outcomes

  1. LC-QSPECT related adverse events

    Time frame: From start of LC-QSPECT imaging through 12 hours following LC-QSPECT imaging

  2. Percentage of enrolled patients who withdraw from the study due to adverse events at least possibly related to LC-QSPECT (as chosen by patients or treating physician team)

    Time frame: From start of LC-QSPECT imaging through 12 hours following LC-QSPECT imaging

  3. Feasibility of conducting LC-QSPECT will be determined by percentage of SPECT scans that can be processed using the investigators' computational method

    Feasibility is defined as at least 80% of scans able to be processed.

    Time frame: Through completion of LC-QSPECT imaging (estimated to be 3 months)

  4. Correlation between the LC-QSPECT measurements and PSA (Spearman Correlation Coefficient)

    Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  5. Correlation between the LC-QSPECT measurements and PSA doubling time (Spearman Correlation Coefficient)

    Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  6. Correlation between the LC-QSPECT measurements and bone-turnover markers (Spearman Correlation Coefficient)

    Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  7. Correlation between the LC-QSPECT measurements and Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire (Spearman Correlation Coefficient)

    * Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation. * The FACT-P scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  8. Correlation between the LC-QSPECT measurements and EuroQol-5 (EQ-5D-5L) questionnaire (Spearman Correlation Coefficient)

    * Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation. * EQ-5D-5L is a descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain \& discomfort, Anxiety \& depression), each of which has five severity levels that are described by statements appropriate to that dimension. Scale Minimum: 0. Scale Maximum: 100. Higher score indicates better outcome.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  9. Correlation between the LC-QSPECT measurements and Brief Pain Inventory (BPI) questionnaire (Spearman Correlation Coefficient)

    * Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation. * BPI score ranges from 0 to 10 with a higher score denoting a higher pain severity.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  10. Correlation between the LC-QSPECT measurements and bone turnover (Spearman Correlation Coefficient)

    Spearman correlation coefficient measures the strength and direction of the linear correlation (dependence) between 2 variables after converting the raw data to ranks, giving a value between +1 and -1 inclusive, where 1 indicates perfect positive correlation, 0 indicates no correlation, and -1 indicates perfect negative correlation.

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  11. Percentage of times that the use of the LC-QSPECT procedure resulted in any changes in treatment plans of the patients

    Time frame: Through completion of Xofigo treatment (estimated to be 6 months)

  12. Performance of the LC-QSPECT procedure using a no-gold-standard evaluation technique.

    * The investigators will use the no-gold-standard technique to assess whether the LC-QSPECT technique yields precise performance on the task of isotope uptake quantification, where slope and noise will be estimated and the noise-to-slope ratio (NSR) will be calculated. * The no-gold-standard technique can be found here: Jha AK, Caffo B, Frey EC. A no-gold-standard technique for objective assessment of quantitative nuclear-medicine imaging methods. Phys Med Biol. 2016 Apr 7;61(7):2780-800. doi: 10.1088/0031-9155/61/7/2780. Epub 2016 Mar 16. PMID: 26982626; PMCID: PMC4921224 and here: Yan Liu, Ziping Liu, Zekun Li, Daniel Thorek, Barry Siegel, Abhinav Jha, "No-gold-standard evaluation of quantitative SPECT methods for alpha-particle radiopharmaceutical therapy", Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P1331

    Time frame: Through completion of LC-QSPECT imaging (estimated to be 3 months)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Abhinav K Jha, Ph.D. · Contacta.jha@wustl.edu · 314-273-2655
    • Abhinav K Jha, Ph.D. · Principal investigator
    • Daniel Thorek, Ph.D. · Sub investigator
    • Tyler J Fraum, M.D. · Sub investigator
    • Richard L Wahl, M.D. · Sub investigator
    • Jingqin (Rosy) Luo, Ph.D. · Sub investigator
    • Richard Laforest, Ph.D. · Sub investigator
    • Hiram Gay, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified SPECT imaging data, quantitative imaging metrics, and limited clinical variables (e.g., demographics, treatment cycle, administered activity, relevant lab values, clinical outcome measures) may be shared with qualified researchers at academic, nonprofit, or industry institutions for secondary analyses of image data, dosimetry, quantitative modeling, or clinical outcomes related to Radium-223 therapy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 12 months after publication of primary results; available for at least 5 years.

Access criteria: Data will be shared through a controlled-access repository. Access will require a brief proposal and a signed data use agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 17 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2025
First posted
Oct 28, 2025
StartEst.
Nov 1, 2026was Sep 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Jul 31, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Nov 1, 2026
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Sep 1, 2026→Nov 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07221825
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Abhinav K Jha, Ph.D.
Contact
a.jha@wustl.edu
314-273-2655
Abhinav K Jha, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion